ArticleJACC. Asia2025
Forecasting Atherosclerotic Cardiovascular Disease in South Asia Until 2040: A Bayesian Modeling Approach.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pristine+™ Everolimus-Eluting Cobalt-Chromium Coronary Stent System: A Prospective, Multicenter Registry.Cardiology research · 2026Article
- Global Burden of Cardiovascular Disease: What Should Be Expected in the Next 25 Years?Current cardiology reports · 2026Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerotic cardiovascular disease (ASCVD) disproportionately impacts low-middle income countries, such as those in South Asia and understanding future ASCVD rates can inform public policy.
objectivesThis study aimed to project the burden of ASCVD in South Asia till 2040.
methodsYearly ischemic heart disease (IHD), stroke, and peripheral artery disease (PAD) counts for South Asia (Afghanistan, Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan, and Sri Lanka) and mid-year population were obtained from Global Burden of Disease (1990-2021) in 5-year age brackets (40-79 years) and estimated mid-year national population (2022-2040) was collected. Age-adjusted prevalence (aaPR) and mortality rate (per 100,000) were projected with Bayesian age-period-cohort models in South Asia (overall, males, and females); trends were reported as the estimated annual percent change (EAPC).
resultsBetween 2021 and 2040, the IHD aaPR in South Asia was projected to increase (2021: 9434.6 [95% CI: 9,432.1-9,437.1], 2040: 9,846.6 [95% CI: 8,800.0-10,893.3], EAPC: 0.23% [95% CI: 0.08%-0.37%]) because of increased rates among females (EAPC: 1.16%; 95% CI: 1%-1.32%). The overall IHD age-adjusted mortality rate will reduce (2021: 254.7 [95% CI: 254.3-255.1), 2040: 224.0 [95% CI: 166.5-281.6), EAPC: -0.67% [95% CI: -1.61% to 0.27%]) but may increase in females (EAPC: 1.16%; 95% CI: 1%-1.32%). Stoke aaPR in South Asia is projected to increase slightly (2021: 1,065.5 [95% CI: 1,064.7-1,066.4], 2040: 1,074.6 [95% CI: 953.7-1,195.5]). The PAD aaPR is projected to increase (2021: 1809.5 [95% CI: 1,808.5-1,810.6], 2040: 1,879.5 [95% CI: 1,684.9-2,074.0], EAPC: 0.26% [95% CI: 0.04%-0.47%]) because of increased rates in females (EAPC: 0.29%; 95% CI: -0.01% to 0.59%).
conclusionsIHD and PAD prevalence rates are projected to increase in South Asia with a disproportionate increase among females.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.